NEW YORK (GenomeWeb) – Australian firm Genome.One and US-based OneOme said today that they have partnered to provide a joint service in Australia to analyze individuals’ genetic disease risks and pharmacogenomic-related variants.
As part of the service launched earlier this month, customers will receive genome sequencing provided by Genome.One and pharmacogenomic testing using OneOme’s RightMed test.
Genome.One, a spinout from the Australia’s Garvan Institute of Medical Research, initially aimed to provide sequencing-based diagnostics for rare diseases. More recently, the company said it would offer whole-genome sequencing to assess risk for a panel of 49 diseases (31 cancer-related conditions and 13 heart conditions) to any curious individual.
OneOme, which began as a joint venture of the Mayo Clinic and early-stage venture firm Invenshure, launched its RightMed test last year. The assays covers 22 genes in which variants are known to contribute to the effectiveness or safety of hundreds of drugs.
Combined with these genetic analyses patients who take advantage of the new service will also receive a more general comprehensive health assessment, offered in partnership with Sydney’s Life First, the companies said.
Additional financial and other terms of the deal were not disclosed.